199 related articles for article (PubMed ID: 32607875)
1. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Yin A; Ettaieb MHT; Swen JJ; van Deun L; Kerkhofs TMA; van der Straaten RJHM; Corssmit EPM; Gelderblom H; Kerstens MN; Feelders RA; Eekhoff M; Timmers HJLM; D'Avolio A; Cusato J; Guchelaar HJ; Haak HR; Moes DJAR
Clin Pharmacokinet; 2021 Jan; 60(1):89-102. PubMed ID: 32607875
[TBL] [Abstract][Full Text] [Related]
2. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
[TBL] [Abstract][Full Text] [Related]
3. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
Arshad U; Taubert M; Kurlbaum M; Frechen S; Herterich S; Megerle F; Hamacher S; Fassnacht M; Fuhr U; Kroiss M
Eur J Endocrinol; 2018 Oct; 179(5):287-297. PubMed ID: 30087117
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
5. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
[TBL] [Abstract][Full Text] [Related]
7. How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
Steenaard RV; Ettaieb MHT; Kerkhofs TMA; Haak HR
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):677-683. PubMed ID: 33886381
[TBL] [Abstract][Full Text] [Related]
8. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Haider MS; Ahmad T; Groll J; Scherf-Clavel O; Kroiss M; Luxenhofer R
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):575-593. PubMed ID: 34287806
[TBL] [Abstract][Full Text] [Related]
9. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
Cazaubon Y; Talineau Y; Feliu C; Konecki C; Russello J; Mathieu O; Djerada Z
Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31683663
[TBL] [Abstract][Full Text] [Related]
11. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
12. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
13. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
14. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
15. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
Kerkhofs TM; Derijks LJ; Ettaieb MH; Eekhoff EM; Neef C; Gelderblom H; den Hartigh J; Guchelaar HJ; Haak HR
Eur J Endocrinol; 2014 Dec; 171(6):677-83. PubMed ID: 25201518
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
17. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
18. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
20. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
